Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2023 Jul;30(7):4087-4094. doi: 10.1245/s10434-023-13319-4. Epub 2023 Mar 11.
The core-needle biopsy (CNB) diagnosis of atypical ductal hyperplasia (ADH) generally mandates follow-up excision, but controversy exists on whether small foci of ADH require surgical management. This study evaluated the upgrade rate at excision of focal ADH (fADH), defined as 1 focus spanning ≤ 2 mm.
We retrospectively identified in-house CNBs with ADH as the highest-risk lesion obtained between January 2013 and December 2017. A radiologist assessed radiologic-pathologic concordance. All CNB slides were reviewed by two breast pathologists, and ADH was classified as fADH and nonfocal ADH based on extent. Only cases with follow-up excision were included. The slides of excision specimens with upgrade were reviewed.
The final study cohort consisted of 208 radiologic-pathologic concordant CNBs, including 98 fADH and 110 nonfocal ADH. The imaging targets were calcifications (n = 157), a mass (n = 15), nonmass enhancement (n = 27), and mass enhancement (n = 9). Excision of fADH yielded seven (7%) upgrades (5 ductal carcinoma in situ (DCIS), 2 invasive carcinoma) versus 24 (22%) upgrades (16 DCIS, 8 invasive carcinoma) at excision of nonfocal ADH (p = 0.01). Both invasive carcinomas found at excision of fADH were subcentimeter tubular carcinomas away from the biopsy site and deemed incidental.
Our data show a significantly lower upgrade rate at excision of focal ADH than nonfocal ADH. This information can be valuable if nonsurgical management of patients with radiologic-pathologic concordant CNB diagnosis of focal ADH is being considered.
核心针活检 (CNB) 诊断非典型导管增生 (ADH) 通常需要后续切除,但对于小病灶 ADH 是否需要手术治疗存在争议。本研究评估了切除局灶性 ADH(fADH)的升级率,定义为 1 个病灶跨越 ≤ 2mm。
我们回顾性地确定了 2013 年 1 月至 2017 年 12 月期间在内部进行的 CNB 中,ADH 是最高风险病变。一名放射科医生评估了影像学与病理学的一致性。两位乳腺病理学家对所有 CNB 切片进行了复查,并根据范围将 ADH 分为 fADH 和非局灶性 ADH。仅包括有随访切除的病例。复查有升级的切除标本切片。
最终的研究队列包括 208 例放射学-病理学一致的 CNB,包括 98 例 fADH 和 110 例非局灶性 ADH。影像学目标是钙化(n=157)、肿块(n=15)、非肿块强化(n=27)和肿块强化(n=9)。切除 fADH 后有 7 例(7%)升级(5 例导管原位癌 (DCIS),2 例浸润性癌),而非局灶性 ADH 切除后有 24 例(22%)升级(16 例 DCIS,8 例浸润性癌)(p=0.01)。在切除 fADH 时发现的 2 例浸润性癌均为远离活检部位的亚厘米管状癌,被认为是偶然发现。
我们的数据显示,切除局灶性 ADH 的升级率明显低于非局灶性 ADH。如果正在考虑对放射学-病理学一致的 CNB 诊断为局灶性 ADH 的患者进行非手术治疗,这些信息可能非常有价值。